Ameritas Investment Partners
PHAT icon

Ameritas Investment Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Ameritas Investment Partners’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.4K Buy
4,463
+936
+27% +$10.7K ﹤0.01% 2273
2026
Q1 		$39.2K Hold
3,527
– – ﹤0.01% 2240
2025
Q4 		$58.5K Hold
3,527
– – ﹤0.01% 2017
2025
Q3 		$41.5K Sell
3,527
-784
-18% -$8.09K ﹤0.01% 2283
2025
Q2 		$41.3K Buy
4,311
+1,216
+39% +$6.73K ﹤0.01% 2309
2025
Q1 		$19.4K Hold
3,095
– – ﹤0.01% 2571
2024
Q4 		$25.1K Hold
3,095
– – ﹤0.01% 2536
2024
Q3 		$56K Hold
3,095
– – ﹤0.01% 2123
2024
Q2 		$31.9K Hold
3,095
– – ﹤0.01% 2386
2024
Q1 		$32.9K Hold
3,095
– – ﹤0.01% 2354
2023
Q4 		$28.3K Hold
3,095
– – ﹤0.01% 2427
2023
Q3 		$32.1K Buy
3,095
+1,507
+95% +$20.7K ﹤0.01% 2323
2023
Q2 		$22.7K Hold
1,588
– – ﹤0.01% 2503
2023
Q1 		$11.3K Hold
1,588
– – ﹤0.01% 2692
2022
Q4 		$13.9K Hold
1,588
– – ﹤0.01% 2704
2022
Q3 		$17K Hold
1,588
– – ﹤0.01% 2601
2022
Q2 		$13K Hold
1,588
– – ﹤0.01% 2754
2022
Q1 		$22K Hold
1,588
– – ﹤0.01% 2522
2021
Q4 		$31K Hold
1,588
– – ﹤0.01% 2423
2021
Q3 		$51K Hold
1,588
– – ﹤0.01% 2148
2021
Q2 		$54K Buy
1,588
+663
+72% +$23.7K ﹤0.01% 2128
2021
Q1 		$35K Hold
925
– – ﹤0.01% 2289
2020
Q4 		$31K Hold
925
– – ﹤0.01% 2259
2020
Q3 		$34K Hold
925
– – ﹤0.01% 2080
2020
Q2 		$30K Hold
925
– – ﹤0.01% 2136
2020
Q1 		$24K Hold
925
– – ﹤0.01% 2076
2019
Q4 		$29K Buy
+925
New +$23.2K ﹤0.01% 2225

Other funds holding PHAT

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Ameritas Investment Partners's PHAT Position: Q2 2026 in Review

Ameritas Investment Partners increased its Phathom Pharmaceuticals (PHAT) stake by 27% in Q2 2026, buying an estimated $10.7K and bringing the position to 4,463 shares worth $48.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2273.

Ameritas Investment Partners first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $58.5K in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Ameritas Investment Partners held 4,463 shares of Phathom Pharmaceuticals worth $48.4K as of Q2 2026.
  • Ameritas Investment Partners bought 936 Phathom Pharmaceuticals shares in Q2 2026, an estimated $10.7K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2273 holding.
  • Ameritas Investment Partners first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Ameritas Investment Partners's Phathom Pharmaceuticals position peaked at $58.5K in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.